A5007512686- Asthma and respiratory diseases
- Sinusitis and nasal conditions
- Allergic Rhinitis and Sensitization
- Eosinophilic Esophagitis
- Health Systems, Economic Evaluations, Quality of Life
- IL-33, ST2, and ILC Pathways
- Schizophrenia research and treatment
- Pharmaceutical Economics and Policy
- Multiple Sclerosis Research Studies
- Nasal Surgery and Airway Studies
- Dermatology and Skin Diseases
- Respiratory and Cough-Related Research
- Olfactory and Sensory Function Studies
- Pharmaceutical studies and practices
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Bipolar Disorder and Treatment
- Lymphoma Diagnosis and Treatment
- Electrolyte and hormonal disorders
- Mycobacterium research and diagnosis
- Mental Health and Psychiatry
- Lipoproteins and Cardiovascular Health
- Pediatric health and respiratory diseases
- Mental Health Treatment and Access
- Gastroesophageal reflux and treatments
- Eosinophilic Disorders and Syndromes
Regeneron (United States)
2018-2024
Harvard University
2024
Temple University
2024
American Academy of Otolaryngology — Head and Neck Surgery
2024
Mental Health Association of Westchester County
2018-2020
Sanofi (France)
2020
University of Mississippi Medical Center
2020
State Street (United States)
2020
American College of Allergy, Asthma and Immunology
2020
Otsuka (United States)
2013-2019
The objective of this study was to estimate the US societal economic burden schizophrenia and update 2002 reported costs $62.7 billion given disease management health care structural changes last decade.A prevalence-based approach used assess direct costs, non-health indirect associated with (ICD-9 codes 295.xx) for 2013, cost adjustments where necessary. Direct were estimated using a retrospective matched cohort design Truven Health Analytics MarketScan Commercial Claims Encounters,...
BackgroundDupilumab blocks the shared receptor component for IL-4 and IL-13, key drivers of type 2 inflammation, including IgE-mediated allergic inflammation in asthma. In LIBERTY ASTHMA QUEST (NCT02414854) study, dupilumab reduced severe asthma exacerbations improved forced expiratory volume 1 second (FEV1) patients with uncontrolled, moderate-to-severe greater efficacy observed elevated inflammatory biomarkers (blood eosinophils fractional exhaled nitric oxide) at baseline.ObjectiveWe...
OBJECTIVE Several second-generation antipsychotic (SGA) drugs have been associated with weight gain, hyperglycemia, and dyslipidemia. We evaluated whether glucose lipid testing increased after the American Diabetes Association (ADA) consensus statement recommending metabolic monitoring for SGA-treated patients. RESEARCH DESIGN AND METHODS Laboratory claims serum were identified an incident cohort of 18,876 adults initiating SGA in a U.S. commercial health plan (2001–2006) control group...
Chronic rhinosinusitis with nasal polyps (CRSwNP) and type 2 asthma share the same inflammatory pathophysiology are frequent comorbidities. Dupilumab, a fully human monoclonal antibody, blocks shared receptor component for interleukin 4 13, which key central drivers of inflammation.We report effect dupilumab vs placebo on outcome measures upper lower airways health-related quality life (HRQoL) in pooled population patients CRSwNP comorbid from phase 3 SINUS-24 (NCT02912468) SINUS-52...
Among patients with chronic rhinosinusitis nasal polyps (CRSwNP), randomized clinical trials (RCTs) of biologics, such as anti-interleukin-4/interleukin-13 (dupilumab) and anti-immunoglobulin E (omalizumab), have demonstrated efficacy compared intranasal corticosteroids (INCS). However, no head-to-head RCTs exist between biologics.To perform an indirect treatment comparison (ITC) the biologics plus INCS versus placebo (INCS) a common comparator.Embase, MEDLINE, Cochrane were searched for in...
BackgroundLoss of smell (LoS) is one the most troublesome and difficult-to-treat symptoms severe chronic rhinosinusitis with nasal polyps (CRSwNP).ObjectiveTo assess impact dupilumab on sense in CRSwNP.MethodsIn randomized SINUS-24 SINUS-52 studies, adults CRSwNP received 300 mg subcutaneously or matching placebo every 2 weeks for 24 52 weeks, respectively. Smell was assessed using daily patient-reported LoS score (0–3) University Pennsylvania Identification Test (UPSIT; 0–40). Data from...
Objectives/Hypothesis The 22‐item Sinonasal Outcome Test (SNOT‐22) is a validated chronic rhinosinusitis health‐related quality‐of‐life outcome (HRQoL) measure; however, SNOT‐22 domains have not been specifically for with nasal polyps (CRSwNP). Study Design Validation of domain structure, using data from 3 randomized, placebo‐controlled, double‐blinded, multicenter clinical trials dupilumab in adults moderate‐to‐severe CRSwNP. Methods Preliminary dimensional structure was derived by...
Abstract Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2‐mediated inflammatory disease high symptom burden and reduced health‐related quality of life (HRQoL). This report aimed to comprehensively understand the effects dupilumab on domains HRQoL, their individual elements, health status in patients severe CRSwNP from phase 3 SINUS‐24 (NCT02912468) SINUS‐52 (NCT02898454) trials. Methods Patients were randomized ( n = 438) or placebo 286) for 24 weeks...
Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type inflammation and has demonstrated treatment benefits patients with atopic dermatitis (AD), asthma, chronic rhinosinusitis nasal polyps (CRSwNP) an acceptable safety profile.This post hoc analysis across five phase 3 studies moderate to severe AD or CRSwNP, evaluated time of onset duration the response.Patients received subcutaneous dupilumab 200/300 mg placebo. Assessments included Eczema Area Severity Index, Peak...
Abstract This observational study assessed the prevalence of co-existing type 2 inflammatory conditions [T2Cs; asthma, atopic dermatitis (AD), allergic rhinitis, and chronic rhinosinusitis with nasal polyps (CRSwNP)] in patients moderate-to-severe (M/S) M/S CRSwNP, or AD, real-world setting. Data from 761 physicians US EUR5 were sourced Adelphi Disease-Specific Programmes covering asthma ( n = 899), CRSwNP 683), AD 1497). At least one T2C was identified 66%, 69%, 46% cohorts, respectively,...
BackgroundComorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substantially contributes to disease burden in patients with asthma. Dupilumab blocks the shared receptor for interleukin (IL) 4 and IL-13, key drivers of type 2 inflammation that play important roles asthma PAR. In LIBERTY ASTHMA QUEST trial (NCT02414854), dupilumab reduced severe exacerbations improved forced expiratory volume 1 second (FEV1) uncontrolled, moderate-to-severe asthma, greater efficacy...
BackgroundDupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation. In phase 3 study (NCT02414854), add-on dupilumab 200 mg/300 mg every weeks, versus placebo, significantly reduced severe asthma exacerbations improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) quality-of-life measures patients with uncontrolled, moderate-to-severe asthma, greater efficacy observed those high...
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 interleukin-13, key drivers 2-mediated inflammation. We report results pooled analyses from randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24...
This study addresses an important gap, as it is the first US nationwide, epidemiologic of ADPKD incidence and prevalence.This 3-year, observational utilized data from Truven Health MarketScan® administrative claims, well cross-sectional National Ambulatory Medical Care Survey (NAMCS). We estimated annual diagnosed prevalence using population-based on over 170 million de-identified patients to provide most current estimates available. The ADPKD-diagnosed was 4.3 per 10,000 in NAMCS, which...
Summary Background Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality life (QoL) EoE patients. Methods The multicountry cross-sectional survey, Adelphi Disease Specific Programme™, collected physician patient-reported HCRU, QOL with past/current proton pump inhibitor use ongoing dysphagia-related symptoms (September to December 2020)...
Study Objective. To compare, in a usual care setting, the effects of rosuvastatin and other 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) on lipid levels goal attainment low-density lipoprotein cholesterol (LDL) from National Cholesterol Education Program (NCEP) third report Adult Treatment Panel (ATP III). Design. Retrospective, longitudinal, cohort study. Data Source. Managed medical pharmacy claims laboratory database. Patients. total 8251 patients starting treatment with...
Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate disability progression, improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple sclerosis. We investigated impact natalizumab on patient-reported outcomes (PROs) a real-world setting. PRO data were collected from enrolled longitudinal study using validated measures administered as surveys before initiated treatment after 3rd, 6th, 12th monthly infusion....
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease high symptom burden. Data are lacking on the comparative health status of patients CRSwNP. This analysis compared baseline physical and mental health-related quality life (HRQoL) overall severe CRSwNP enrolled in Phase 3 clinical trial general population norms other chronic diseases.In this post hoc cross-sectional data from SINUS-24 study (NCT02912468), HRQoL was measured using 36-item Short...
Background: Loss of sense smell is one the most burdensome symptoms chronic rhinosinusitis with nasal polyps (CRSwNP) but its relationship to sinus disease on imaging unclear. Dupilumab improves and radiographic severity in patients CRSwNP. We investigated opacification loci olfactory impairment dupilumab efficacy CRSwNP from SINUS-24/SINUS-52 (NCT02912468/NCT02898454) studies. Methods: Sinus was evaluated using Lund-Mackay computed tomography (LMK-CT) score patient-reported loss (LoS)...
Abstract Objectives To assess the severity of top 5 22‐item Sino‐Nasal Outcome Test (SNOT‐22) items ranked most important by patients with chronic rhinosinusitis nasal polyps (CRSwNP), effect dupilumab on these items, and their association objective disease measures. Study Design Post hoc analysis SINUS‐24 (NCT02912468) SINUS‐52 (NCT02898454) clinical trials. Setting Multinational, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group studies. Methods Patients SNOT‐22...